Disc Medicine (IRON) Cash from Financing Activities (2020 - 2026)

Disc Medicine (IRON) has reported Cash from Financing Activities for 7 consecutive years, with $32.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 3525.0% year-over-year to $32.3 million; the TTM figure through Jun 2026 stood at $262.3 million (down 4.4% YoY), while the FY2025 annual figure was $473.4 million, up 116.85% from the prior year.
• Cash from Financing Activities rose to $32.3 million in Q2 2026 per IRON's latest filing, from $1.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $244.3 million in Q1 2025 and bottomed at $22000.0 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $61.9 million across 5 years, with a median of $13.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.97% — and 2023, when it jumped 178801.16%.
• Disc Medicine's Cash from Financing Activities stood at $148.8 million in 2022, then tumbled by 94.79% to $7.8 million in 2023, then surged by 271.19% to $28.8 million in 2024, then jumped by 652.43% to $216.7 million in 2025, then slumped by 85.08% to $32.3 million in 2026.
• Business Quant data shows IRON's Cash from Financing Activities at $32.3 million in Q2 2026, $1.7 million in Q1 2026, and $216.7 million in Q4 2025.